Some Apple employees have become disillusioned with the group's culture, where some have thrived while others feel sidelined.Technologyread more
Biden has shown staying power at the top of a jammed Democratic field even as polling numbers for Sanders, Warren and Harris wax and wane.2020 Electionsread more
The FDIC on Tuesday votes to approve a five-agency revision of the post-crisis regulation known as the Volcker Rule.Financeread more
Stocks slipped on Tuesday as investors digested a sharp rebound from a strong sell-off last week.US Marketsread more
For investors still haunted by last week's monster sell-off, the market's comeback is set to last, according to J.P. Morgan's quant guru.Marketsread more
The launch follows a "preview" earlier this month that allowed only limited customers to apply.Technologyread more
"The hawks on the Fed are going to be gunning for no more rate cuts, which is obviously not what the market wants," says CNBC's Jim Cramer.Marketsread more
U.S. interest rates will keep falling and follow global interest rates all the way down to zero, hedge fund manager Kyle Bass said.Marketsread more
Lyft's earlier-than-anticipated share lockup expiration could actually serve to boost the ride-sharing company's stock, says trading expert Dan Nathan.Options Actionread more
An under-the-radar hedge fund is ruling the industry with a nearly 30% return this year so far, and it's more than doubling its bet on gold.Marketsread more
Billionaire investor Ron Baron remains bullish on Tesla despite "some self-inflicted wounds" and a 32% drop in its stock price so far this year.Autosread more
Balaji Srinivasan, CEO of bitcoin start-up 21.co, and Jim O'Neill, the managing director of investment firm Mithril Capital Management, were both scheduled to meet with Trump Thursday afternoon. Both "are being considered for positions in the FDA," incoming White House press secretary Sean Spicer said on a daily briefing call.
Srinivasan, also a partner at venture firm Andreessen Horowitz, is an expert in the subjects of digital payments and computational biology, and teaches at Stanford University. Srinivasan's expertise in health regulation stems back to a start-up he co-founded, Counsyl, which offers DNA screening, especially for people considering having children.
Srinivasan has openly criticized the FDA, saying that "big bad pharma does exist, but is only half the story. FDA sets the incentives."
O'Neill, who has previously been mentioned as a potential FDA pick, formerly advised top players at Heath and Human Services on drug and research investments. He's also been outspoken about the state of healthcare regulation, speaking on the issue of aging at a conference in 2014.
"The pharma industry's approach to aging certainly counts as long over due for innovation," O'Neill said, citing regulatory controls as an obstacle.
That viewpoint is not unlike that of Thiel, who reiterated to the New York Times this week: "Science is technology's older brother who has fallen on hard times ... I have some strong opinions on this. At the F.D.A. today, aging is still not an indication for disease. And you're not allowed to develop drugs that could stop aging. We have not even started yet."
Thiel, PayPal co-founder, libertarian and Trump transition team member, has relationships with both Srinivasan and O'Neill. Srinivasan's 21.co is backed by Thiel, and Thiel is the co-founder and chair at Mithril. O'Neill previously ran the Thiel Foundation.
"Jim O'Neill has extensive experience in government and in Silicon Valley. He is a strong candidate for any of several key positions," a spokesman for Thiel told CNBC in December.
O'Neill and Srinivasan aren't the first Thiel darlings to appear before Trump: Alex Karp, CEO of Thiel's cybersecurity company Palantir, has also attended meetings. Trae Stephens, a principal at Thiel's Founders Fund, which has invested in Palantir, and a former Palantir employee himself, has also been tapped for the transition team working on defense, according to Bloomberg.
Trump transition team's code of ethics requires Thiel disqualify himself from involvement in any particular transition matter which may directly conflict with a financial interest, and address any appearance of a conflict with the general counsel. A spokesperson for Thiel previously declined to say whether he had signed the agreement.
Transforming healthcare will be a top priority for the incoming administration: Trump said he would stop the industry from "getting away with murder " in his first post-election press conference this week.